AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alnylam Pharmaceuticals: Chardan Capital maintains a 'Buy' Rating, The Target Price is $400
ByAinvest
Friday, Aug 1, 2025 8:00 am ET1min read
Chardan Capital maintains 'Buy' rating on Alnylam Pharmaceuticals(ALNY).
The target price is $400, compare with $325 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-08-01 | UBS | Maintains | Buy | Buy | $550 | $403 |
| 2025-08-01 | Barclays | Maintains | Overweight | Overweight | $460 | $329 |
| 2025-08-01 | Scotiabank | Maintains | Sector Outperform | Sector Outperform | $450 | $342 |
| 2025-08-01 | Piper Sandler | Maintains | Overweight | Overweight | $449 | $304 |
| 2025-08-01 | Raymond James | Reiterates | Outperform | Outperform | $424 | $370 |
| 2025-07-31 | Needham | Maintains | Buy | Buy | $478 | $377 |
[Recent Earning Results] Alnylam Pharmaceuticals posted the Q2 of its 2025 financial results on 7/31/2025, reporting total revenue of USD 1367.88 million in the first half of the year, up 18.52% from USD 1154.16 million year over year, reporting net income of USD -123.76 million in the first half of the year, expanding 49.42% from USD -82.82 million year over year.
[Company Profile] Alnylam Pharmaceuticals, Inc. is a Delaware corporation that was formed in May 2003. The company is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. The company believes that drugs that work through RNAi have the potential to become a broad new class of drugs, like small molecule, protein and antibody drugs. Using the company's intellectual property and the expertise the company has built in RNAi, the company is developing a set of biological and chemical methods and know-how that the company applies in a systematic way to develop RNAi therapeutics for a variety of diseases.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet